|
|Section2= |Section3= }} Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.〔, Sept 2009〕 One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009. In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma. MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required. ==Mechanism of action== It works by inhibiting mainly histone deacetylase 1 (HDAC1), but also HDAC2, HDAC3, and HDAC11.〔(MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Mocetinostat」の詳細全文を読む スポンサード リンク
|